Novo Nordisk (NOVOB DC) announces that the EU commission has approved more effective dose of injectable Wegovy for adults with obesity; study people lost about 21% of their body weight on average

Novo Nordisk's announcement regarding the EU's approval of a more effective dose of Wegovy is significant as it could enhance the drug's market potential, particularly in treating obesity.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Mondelez (MDLZ) reaffirms its long term targets; organic net revenue +3-5% and Adj. EPS "high single digit" FCF "more than" USD 3bln

ServiceNow (NOW) CEO and CFO terminate stock trading plan; the CEO announces their intent to purchase USD 3mln shares

Novo Nordisk (NOVOB DC) announces that the EU commission has approved more effective dose of injectable Wegovy for adults with obesity; study people lost about 21% of their body weight on average

[MARKET UPDATE] XAU, USTs & Crude futures slip following comments via the Iranian Foreign Minister who noted they have reached understanding on main principles with the US; Brent Apr'26 fell from circa. USD 68.41/bbl to USD 67.30/bbl within a few minutes

Iran's Foreign Minister says we have reached understanding on main principles with the US, the two parties will welcome potential agreement documents and exchange them, does not mean an agreement will be reached soon but the path has started

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The substantial average weight loss reported in studies not only strengthens the product's efficacy profile but could also positively impact sales forecasts, positioning Novo Nordisk favorably against competitors in the health sector.

Related headlines

The whole workspace, free to try.

Try it free